7210 Wareham Drive, Tampa, FL 33647
Sept. 9, 2025 According to Reuters, “The U.S. Food and Drug Administration is tightening oversight of imports of GLP-1 drug ingredients, used for weight loss and diabetes, amid concerns that many of the items may be adulterated and pose a safety risk. The move comes as the FDA cracks down on unapproved compounded drugs, which […]
FDA Tightens Oversight of GLP-1 Ingredients Imports Read More »
Sept. 8, 2025 WW today announced the launch of Weight Watchers for Menopause, a program that is designed to support women through every stage of the menopause journey, from perimenopause to post-menopause. To launch the program, WeightWatchers is partnering with Grammy and Emmy Award-winning and Oscar-nominated actress, producer, entrepreneur, and health advocate Queen Latifah as
Queen Latifah To Pitch New Weight Watchers Menopause Program Read More »
Sept. 3, 2025 WW announced the appointment of Alejandro Bethlen as Executive Vice President, International, effective immediately. In this role, Bethlen will oversee WeightWatchers’ business outside of the United States, driving international growth and innovation across the Company’s global footprint. “Alejandro’s international experience and commercial leadership make him uniquely suited to advance our growth outside
Weight Watchers Hires New International V.P. Read More »
August 11, 2025 The company emerged from its financial reorganization process on June 24, 2025. According to Tara Comonte, CEO of Weight Watchers: “This marks the beginning of an exciting new chapter for the Company, one that’s grounded in stronger financial footing and a clear sense of opportunity. With greater flexibility to invest, we’re accelerating
Weight Watchers Reports Q2 2025 Results Read More »
August 6, 2025 Sales of Novo Nordisk’s injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of U.S. tariffs, coupled with continued competition from compounded drugs sold illegally. Novo Nordisk said sales of medications such as Ozempic – which mimic the GLP-1 gut hormone that regulates blood sugar levels and
Novo Nordisk Obesity Drugs Sales Slow – Compounders Still Selling illegally Read More »
August 5, 2025 Noom is not giving up in the fight to provide GLP-1 drugs, despite pressure from Novo and Eli Lilly to stop selling compounded meds. It is now offering a “micro dose” plan. This program provides access to GLP-1 medication (if prescribed by a clinician), but at a lower, “microdose” level compared to
Noom To Offer GLP-1 Microdose Plan Read More »
August 4, 2025 “We are working diligently to transform our business as we look to help more people achieve optimal metabolic health,” said Dan Chard, CEO of Medifast. “We’re focused on new and impactful ways to reignite coach growth and productivity through targeted initiatives that aim to enhance our offering, expand tailored client solutions, and
Medifast Reports Q2 Results – Slide Continues Read More »
July 8, 2025 There is no doubt that the number of weight loss (bariatric) surgeries has fallen, due to the competition from the GLP-1 drugs, since 2022. Marketdata (the owner of DietBusinessWatch.com) has estimated that procedure volume has declined 25% since 2022, to 211,000 procedures in 2024, as Americans opted for the new drugs instead.
How Are Weight Loss Surgeons Coping With Less Surgeries? Read More »
July 2, 2025 Weight Watchers announced an expanded collaboration with Novo Nordisk, which includes increased access to authentic, FDA-approved Wegovy® (semaglutide) injection through Weight Watchers Clinic. As part of the collaboration, Weight Watchers Clinic members will benefit from a simplified prescription process via NovoCare® Pharmacy. CenterWell Pharmacy®, which serves as the dispensing pharmacy for the
Weight Watchers Expands Collaboration With Novo Nordisk Read More »
June 24, 2025 Hims & Hers stock plummeted nearly 35% Monday after Novo Nordisk announced it was ending a collaboration to make its blockbuster weight-loss drug, Wegovy, available on Hims’ telehealth platform. Novo Nordisk said that Hims & Hers was breaking the law by continuing to sell copycat semaglutide, the key ingredient in Wegovy, alongside
Novo Nordisk Ends Wegovy Sales Deal With Hims & Hers Read More »